INmune Bio GAAP EPS of -$2.11 beats by $0.14, revenue of $0.01M in-line
Source: SeekingAlpha
2025-03-27 16:11:33 ET
More on INmune Bio
- INmune Bio: CORDStrom Is A Game-Changer, As Investors Await Alzheimer's Results
- INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025
- INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers
- Seeking Alpha’s Quant Rating on INmune Bio
- Historical earnings data for INmune Bio
Read the full article on Seeking Alpha
For further details see:
INmune Bio GAAP EPS of -$2.11 beats by $0.14, revenue of $0.01M in-line
INmune Bio Inc.
NASDAQ: INMB
INMB Trading
-5.44% G/L:
$1.565 Last:
646,918 Volume:
$1.66 Open:
INMB Latest News
May 15, 2026 08:00:00 am
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro(TM) PlatformMay 14, 2026 08:00:00 am
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's DiseaseINMB Stock Data
$100,001,939
20,608,626
3.69%
19
N/A
Biotechnology & Life Sciences
Healthcare
US
Boca Raton
